Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis, Glenmark, Centrient Act To Tackle COVID-19 Crisis

As Beximco Generates Employment With PPE Manufacturing

Executive Summary

While Novartis is continuing to provide hydroxychloroquine for ongoing investigator-initiated trials and support for study of a potential vaccine, it has decided to stop sponsoring hydroxychloroquine clinical trials. Meanwhile, Natco has announced donations of chloroquine phosphate for clinical trials, while Centrient and Beximco have provided PPE for healthcare workers.

You may also be interested in...



Glenmark Makes Progress On Favipiravir Clinical Trials

The Phase III clinical trials of Glenmark’s FabiFlu demonstrate that the oral antiviral could prevent mild and moderate Covid-19 patients from progressing to acute respiratory distress syndrome or dying. Glenmark plans to release the clinical trial data soon.

Centrient Hits Milestone On Antimicrobial Resistance

Centrient has declared itself one of the first companies to announce progress in achieving Predicted No-Effect Concentration discharge targets for the largest part of its antibiotics – the firm’s semi-synthetic penicillin active pharmaceutical ingredients portfolio. In addition, 97% of Centrient’s SSP finished-dose formulation products are also PNEC compliant, according to the firm.

WHO Stops Clinical Trials Involving Hydroxychloroquine And HIV Drugs

The WHO’s “Solidarity” trial investigators have decided to interrupt the trials with immediate effect since the clinical trial found that hydroxychloroquine and lopinavir/ritonavir “produced little or no reduction in the mortality of the hospitalized COVID-19 patients.”

Topics

Related Companies

UsernamePublicRestriction

Register

SC031354

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel